This week in therapeutics




Licensing status

Publication and contact information


Ovarian cancer

HNF1 homeobox B (HNF1B)

Patient studies suggest genetic and epigenetic variation in HNF1B could be useful for the classification and prognosis of ovarian cancers. In ovarian tumor samples, epigenetic DNA analysis showed that the HNF1B promoter region was methylated in 42% of serous tumors, whereas methylation levels were 0% in clear cell ovarian tumors. In samples from 44,308 subjects, genetic analysis showed that the rs7405776 SNP in HNF1B was associated with increased risk for invasive serous ovarian cancer, whereas the rs11651755 SNP in HNF1B was associated with decreased risk for clear cell ovarian cancer. Next steps could include developing an assay to classify ovarian cancers based on genetic and epigenetic variation in HNF1B.

SciBX 6(14); doi:10.1038/scibx.2013.336
Published online April 11, 2013

Patent and licensing status unavailable

Shen, H. et al. Nat. Commun.; published online March 27, 2013;
Contact: Celeste Leigh Pearce, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, Calif.

Contact: Ellen L. Goode, Mayo Clinic, Rochester, Minn.